Finance

Lists
IART:NASDAQ
Integra Lifesciences Holdings Corp
$15.54
0.00%
(0.00) 1D
Sep 10, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for IART...
Mkt. cap
1.21B
Avg. vol.
700.08K
Volume
5.00
52-wk high
$20.49
52-wk low
$8.70
EPS
-$0.10
Beta
1.21
Shares outstanding
77.77M
No. of employees
4K
Mkt. cap
1.21B
Avg. vol.
700.08K
Volume
5.00
52-wk high
$20.49
52-wk low
$8.70
EPS
-$0.10
Beta
1.21
Shares outstanding
77.77M
No. of employees
4K
News stories
From web sources and news partners
Profile
Integra LifeSciences Holdings Corporation is a global medical device manufacturing company headquartered in Princeton, New Jersey. Founded in 1989, the company manufactures products for skin regeneration, neurosurgery, reconstructive and general surgery. Integra artificial skin became the first commercially reproducible skin tissue used to treat severe burns and other skin wounds. Wikipedia
About Integra Lifesciences Holdings Corp
CEO-
Employees4.43K
Founded1989
HeadquartersPrinceton, New Jersey, United States
SectorMedical device
Websiteintegralife.com
Analyst ratings
Based on 8 analysts giving stock ratings to IART in the past 3 months
Hold
Buy
1
Hold
6
Sell
1
12-month forecast
Based on 8 Wall Street analysts offering 12 month price targets for IART in the last 3 months.
Highest
Current $15.54
$25.00 (+60.88%)
Average
$19.29 (+24.13%)
Lowest
$17.00 (+9.40%)
Analyst
Recommendation
Action
Price target
Projected
Date
Joanne Wuensch
Citi
Hold
Maintained
$19.00
+22.3%
08/13/2026
Robbie Marcus
J.P. Morgan
Sell
Maintained
$17.00
+9.4%
08/04/2026
Vik Chopra
BMO Capital
Hold
Maintained
$18.00
+15.8%
07/30/2026
Larry Biegelsen
Wells Fargo
Hold
Maintained
$18.00
+15.8%
07/30/2026
Patrick Wood
UBS
Hold
Initiated
$19.00
+22.3%
07/28/2026
Richard Newitter
Truist Financial
Hold
Maintained
$19.00
+22.3%
07/16/2026
Ravi Misra
Truist Financial
Hold
Maintained
$19.00
+22.3%
07/16/2026
Unknown Analyst
BMO Capital
Hold
Initiated
$19.00
+22.3%
07/08/2026
Ryan Zimmerman
BTIG
Hold
Maintained
-
-
06/22/2026
David Toung
Argus Research
Buy
Upgraded
$25.00
+60.9%
06/17/2026
Travis Steed
Bank of America Securities
Sell
Maintained
-
-
05/14/2026
Unknown Analyst
Jefferies
Buy
Maintained
$27.00
+73.7%
05/06/2026
Last report
Jul 29, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
$0.56 / $0.48
+16.50%beat
Revenue / Est. (USD)
418.76M / 417.54M
+0.29%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
402.06M
434.92M
391.92M
418.76M
Cost of goods sold
172.23M
189.79M
163.50M
185.09M
Cost of revenue
172.23M
189.79M
163.50M
185.09M
Research and development expenses
19.28M
19.34M
18.70M
22.39M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
166.94M
167.92M
165.16M
167.22M
Operating expense
189.94M
191.03M
187.64M
193.38M
Total operating expenses
362.17M
380.82M
351.13M
378.47M
Operating income
39.89M
54.10M
40.79M
40.29M
Other non operating income
-5.04M
21.30M
-2.95M
-4.62M
EBT including unusual items
-6.82M
4.31M
-2.41M
4.74M
EBT excluding unusual items
22.15M
34.00M
28.15M
27.00M
Income tax expense
-1.42M
6.01M
2.21M
262.00K
Effective tax rate
20.81%
139.54%
-91.66%
5.52%
Other operating expenses
-
-
-
-
Net income
-5.40M
-1.70M
-4.62M
4.48M
Net profit margin
-1.34%
-0.39%
-1.18%
1.07%
Earnings per share
0.54
0.83
0.54
0.56
Interest and investment income
4.98M
4.36M
4.11M
4.27M
Interest expense
-22.72M
-23.67M
-22.46M
-22.99M
Net interest expenses
-17.74M
-19.31M
-18.36M
-18.73M
Depreciation and amortization charges
-
-
-
-
EBITDA
78.41M
92.53M
79.22M
78.43M
Gain or loss from assets sale
-4.00K
-
90.00K
643.00K
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps